The Pharmacoepidemiology Program at Johns Hopkins was re-instated in 2007. It is directed by Dr. Jodi Segal in the Division of General Internal Medicine. The Program has attracted interested faculty and students from the Departments of Medicine and Epidemiology, and the hospital pharmacy staff and residents. Lectures have been about novel pharmacoepidemiology methods and advances in pharmaceutical policy from faculty from Johns Hopkins, the University of Maryland, the University of Baltimore, and senior staff from the Food and Drug Administration.

Johns Hopkins Bloomberg School of Public Health has had for many years a week long Summer Institute course on Pharmacoepidemiology; in 2010, a full-term course on Pharmacoepidemiology Methods was added in the Department of Epidemiology directed by Dr. Segal and Dr. Kenneth Shermock. As interest grows, additional courses will be added, with plans for an advanced methods course and a course on pharmacovigilance.

The Pharmacoepidemiology Program has been important in a number of recently funded grants and contracts.  The Partnership in Applied Comparative Effectiveness Science initiative is a large contract with the FDA for the purpose of advancing methods for the evaluation of the comparative effectiveness of drugs and devices. This initiative, led by Dr. Segal, involves a number of investigators in the Departments of Medicine, Oncology and Biostatistics. The Agency for Healthcare Research and Quality recently re- funded the Developing Evidence to Inform Decisions about Effectiveness  (DEcIDE) Research Network which involves local investigators in pharmacoepidemiology research largely in the fields of diabetes research and research on chronic kidney disease.